Citius Oncology, Inc.
CTOR
$0.70
$0.022.64%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.34% | 9.31% | 33.00% | 52.54% | 64.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.60% | 14.34% | 34.48% | 48.88% | 49.27% |
| Operating Income | 0.02% | -14.34% | -34.48% | -48.88% | -49.27% |
| Income Before Tax | -0.87% | -15.22% | -35.33% | -48.88% | -49.27% |
| Income Tax Expenses | 51.80% | 83.47% | 62.60% | 41.74% | 20.87% |
| Earnings from Continuing Operations | -2.41% | -17.08% | -36.13% | -48.65% | -48.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.41% | -17.08% | -36.13% | -48.65% | -48.22% |
| EBIT | 0.02% | -14.34% | -34.48% | -48.88% | -49.27% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 6.90% | -9.65% | -29.29% | -42.76% | -44.39% |
| Normalized Basic EPS | 8.27% | -7.96% | -28.62% | -43.16% | -45.53% |
| EPS Diluted | 6.90% | -9.65% | -29.29% | -42.76% | -44.39% |
| Normalized Diluted EPS | 8.27% | -7.96% | -28.62% | -43.16% | -45.53% |
| Average Basic Shares Outstanding | 11.84% | 7.66% | 5.32% | 3.82% | 2.32% |
| Average Diluted Shares Outstanding | 11.84% | 7.66% | 5.32% | 3.82% | 2.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |